The short answer
Both are taken as tablets, but only oral semaglutide is a peptide. It reaches the circulation with the help of the absorption enhancer SNAC and requires a fasting window and a defined volume of water. Orforglipron has no peptide bonds, needs no enhancer, and can be taken at any time with no food or water conditions.
Key facts
- Oral semaglutide
- Peptide, requires SNAC enhancer
- Orforglipron
- Small molecule, no enhancer
- Semaglutide dosing conditions
- Fasting window, defined water volume
- Orforglipron conditions
- None (any time of day)
- Receptor site
- Orthosteric vs transmembrane allosteric
- ACHIEVE-3
- Orforglipron > oral semaglutide in T2D
The same route, two completely different solutions
Getting a GLP-1 agonist into the bloodstream through the stomach has two possible answers. Protect a fragile peptide well enough that some of it survives, or design a molecule that was never fragile. Oral semaglutide took the first route; orforglipron took the second. Both produce tablets, and almost nothing else about them is comparable.
How SNAC works and what it costs
Salcaprozate sodium is co-formulated with oral semaglutide. It raises pH locally around the dissolving tablet, shielding the peptide from acid and pepsin, and transiently increases permeability of the gastric mucosa so a fraction of the dose crosses. The mechanism depends on conditions in the stomach, which is where the dosing instructions come from: an empty stomach, a small defined volume of water, and a wait before eating.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why orforglipron has no such conditions
It contains no peptide bonds, so there is nothing for pepsin, trypsin or DPP-4 to cleave, and no reason to shield it. It was also designed from the start for permeability, with polar groups positioned to balance solubility against membrane crossing. Nothing about its absorption depends on gastric conditions, so there is nothing to instruct the patient about.
The receptor difference underneath
Oral semaglutide binds the GLP-1 receptor where the natural hormone does, across a broad extracellular surface. Orforglipron cannot, because a small molecule has no way to cover that area, so it binds a hydrophobic pocket in the transmembrane domain and acts allosterically. Same receptor, same downstream signalling, entirely different point of contact.
Head to head
The ACHIEVE-3 study, reported in February 2026, found orforglipron produced greater weight reduction than oral semaglutide in adults with insufficiently controlled type 2 diabetes. That is a direct comparison of the two oral approaches in the same trial, which is more informative than comparing headline figures across separate studies.
Quick reference
| Oral semaglutide | Orforglipron | |
|---|---|---|
| Molecule class | Peptide | Small molecule |
| Absorption enhancer | SNAC required | None |
| Food/water conditions | Yes (fasting window) | None |
| Receptor site | Extracellular orthosteric | Transmembrane allosteric |
| Protease susceptible | Yes, hence SNAC | No |
| UK status | Authorised | Authorised 10 Aug 2026 |
Frequently asked questions
Is one better than the other?
ACHIEVE-3 reported greater weight reduction with orforglipron in adults with insufficiently controlled type 2 diabetes. Beyond that, they differ most in dosing convenience.
What happens if oral semaglutide is taken with food?
Absorption falls. The SNAC mechanism depends on gastric conditions, which is why the dosing instructions exist.
Could a peptide ever be taken orally without an enhancer?
Not at this size and structure. The barriers are acid, proteases and permeability, and all three follow from the peptide backbone.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Aleniglipron? The Second Oral Small-Molecule GLP-1Aleniglipron is an oral non-peptide GLP-1 agonist from Structure Therapeutics. ACCESS reported 12.1% at 36 weeks; ACCESS II reported 15.3% absolute at 44 weeks.
- What Is Semaglutide? Structure, Mechanism and EvidenceSemaglutide is a GLP-1 analogue with 94% homology to native GLP-1. Its structure, the C18 diacid that gives it a weekly half-life, and the SELECT outcome data.
- What Is Tirzepatide? The First Dual Incretin AgonistTirzepatide is a dual GIP and GLP-1 receptor agonist built on a GIP backbone. SURMOUNT-1 reported up to 22.5% weight reduction over 72 weeks.
- Semaglutide vs Tirzepatide: What the Direct Comparison ShowedSURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7% mean reduction. The full comparison, including tolerability.
- What Is the Incretin Effect?Oral glucose produces far more insulin than the same glucose given intravenously. That gap is the incretin effect, and this whole drug class exploits it.